UA117045C2 - Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування - Google Patents
Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосуванняInfo
- Publication number
- UA117045C2 UA117045C2 UAA201606954A UAA201606954A UA117045C2 UA 117045 C2 UA117045 C2 UA 117045C2 UA A201606954 A UAA201606954 A UA A201606954A UA A201606954 A UAA201606954 A UA A201606954A UA 117045 C2 UA117045 C2 UA 117045C2
- Authority
- UA
- Ukraine
- Prior art keywords
- hybrid protein
- growth
- fusion protein
- inhibiting angiogenesis
- protein inhibiting
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 230000006444 vascular growth Effects 0.000 abstract 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 abstract 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000058223 human VEGFA Human genes 0.000 abstract 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Винахід стосується гібридного білка для пригнічення ангіогенезу або судинного росту, який складається з фрагмента рецептора VEGF людини та Fc-фрагмента імуноглобуліну людини. Також винахід стосується нуклеотидної послідовності, що кодує гібридний білок, вектора експресії, клітини-хазяїна, що експресує гібридний білок, способу одержання гібридного білка, фармацевтичної композиції, що містить гібридний білок, та застосування гібридного білка для виготовлення лікарського засобу для лікування захворювання, спричиненого ангіогенезом або судинним ростом.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410035738 | 2014-01-25 | ||
| PCT/CN2015/071434 WO2015110067A1 (zh) | 2014-01-25 | 2015-01-23 | 一种抑制血管新生或生长的融合蛋白及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA117045C2 true UA117045C2 (uk) | 2018-06-11 |
Family
ID=53680846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201606954A UA117045C2 (uk) | 2014-01-25 | 2015-01-23 | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9657084B2 (uk) |
| EP (1) | EP3098241B1 (uk) |
| JP (1) | JP6071099B1 (uk) |
| KR (1) | KR101789501B1 (uk) |
| CN (1) | CN104804097B (uk) |
| AU (1) | AU2015208482B2 (uk) |
| CA (1) | CA2935610C (uk) |
| ES (1) | ES2648809T3 (uk) |
| IL (1) | IL246528B (uk) |
| MX (1) | MX368442B (uk) |
| NZ (1) | NZ721607A (uk) |
| PE (1) | PE20170142A1 (uk) |
| RU (1) | RU2634406C1 (uk) |
| UA (1) | UA117045C2 (uk) |
| WO (1) | WO2015110067A1 (uk) |
| ZA (1) | ZA201604362B (uk) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| PT2944306T (pt) | 2006-06-16 | 2021-02-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| BR112013017752A8 (pt) | 2011-01-13 | 2018-01-09 | Regeneron Pharma | uso de um antagonista do vegf e formulação farmacêutica |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017084616A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| CN106279435B (zh) * | 2016-08-16 | 2019-06-07 | 新乡医学院 | 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用 |
| WO2019083171A2 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 큐로진생명과학 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물 |
| KR102807611B1 (ko) * | 2017-11-10 | 2025-05-14 | 싸토리우스 바이오애널리티컬 인스트루먼츠, 아이엔씨 | 생세포 시각화 및 분석 |
| EP3716992B1 (en) | 2017-11-30 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| SG11202007130RA (en) | 2018-01-26 | 2020-08-28 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CN116715749B (zh) * | 2023-03-20 | 2024-04-09 | 吉林大学 | 一种与胶原具有特异结合能力vegf活性抑制蛋白及其制备方法与应用 |
| CN117535299B (zh) * | 2023-10-27 | 2024-12-06 | 北京生物制品研究所有限责任公司 | 分离的核酸分子、重组病毒或其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1608685T3 (da) | 2003-03-28 | 2007-06-11 | Regeneron Pharma | VEGF antagonister til behandlingen af diabetes |
| JP2007529418A (ja) | 2003-05-28 | 2007-10-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆアンタゴニストの使用による角膜移植拒絶を処置する方法 |
| JP4680997B2 (ja) * | 2004-06-08 | 2011-05-11 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管新生を阻害するキメラタンパク質およびその利用 |
| JP2008502738A (ja) | 2004-06-10 | 2008-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
| CN100471872C (zh) * | 2005-11-04 | 2009-03-25 | 余波 | 包含vegf受体片段的优化融合蛋白质及其医疗应用 |
| US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN101279092B (zh) * | 2007-04-02 | 2010-10-27 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用 |
| CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
-
2015
- 2015-01-23 JP JP2016544126A patent/JP6071099B1/ja active Active
- 2015-01-23 UA UAA201606954A patent/UA117045C2/uk unknown
- 2015-01-23 MX MX2016008776A patent/MX368442B/es active IP Right Grant
- 2015-01-23 PE PE2016001099A patent/PE20170142A1/es unknown
- 2015-01-23 RU RU2016126023A patent/RU2634406C1/ru active
- 2015-01-23 KR KR1020167017551A patent/KR101789501B1/ko active Active
- 2015-01-23 EP EP15739893.4A patent/EP3098241B1/en active Active
- 2015-01-23 CA CA2935610A patent/CA2935610C/en active Active
- 2015-01-23 US US15/109,422 patent/US9657084B2/en active Active
- 2015-01-23 CN CN201510036141.3A patent/CN104804097B/zh active Active
- 2015-01-23 AU AU2015208482A patent/AU2015208482B2/en active Active
- 2015-01-23 NZ NZ721607A patent/NZ721607A/en unknown
- 2015-01-23 ES ES15739893.4T patent/ES2648809T3/es active Active
- 2015-01-23 WO PCT/CN2015/071434 patent/WO2015110067A1/zh not_active Ceased
-
2016
- 2016-06-28 ZA ZA2016/04362A patent/ZA201604362B/en unknown
- 2016-06-29 IL IL246528A patent/IL246528B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3098241A4 (en) | 2017-03-08 |
| WO2015110067A1 (zh) | 2015-07-30 |
| KR101789501B1 (ko) | 2017-10-26 |
| NZ721607A (en) | 2017-05-26 |
| EP3098241A1 (en) | 2016-11-30 |
| CN104804097A (zh) | 2015-07-29 |
| RU2634406C1 (ru) | 2017-10-26 |
| KR20160085362A (ko) | 2016-07-15 |
| US9657084B2 (en) | 2017-05-23 |
| MX368442B (es) | 2019-10-02 |
| JP6071099B1 (ja) | 2017-02-01 |
| CA2935610C (en) | 2018-01-02 |
| MX2016008776A (es) | 2016-11-08 |
| IL246528B (en) | 2018-01-31 |
| PE20170142A1 (es) | 2017-04-02 |
| BR112016015187A2 (pt) | 2018-06-05 |
| AU2015208482B2 (en) | 2017-02-02 |
| AU2015208482A1 (en) | 2016-07-14 |
| EP3098241B1 (en) | 2017-10-25 |
| JP2017505118A (ja) | 2017-02-16 |
| CN104804097B (zh) | 2019-02-22 |
| US20170002056A1 (en) | 2017-01-05 |
| HK1212716A1 (zh) | 2016-06-17 |
| CA2935610A1 (en) | 2015-07-30 |
| ES2648809T3 (es) | 2018-01-08 |
| ZA201604362B (en) | 2017-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA117045C2 (uk) | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування | |
| MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
| NZ749355A (en) | Anti-tim-3 antibodies and methods of use thereof | |
| IL251319B1 (en) | Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use | |
| MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
| SG10201707267RA (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
| HK1258726A1 (zh) | 嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预 | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
| UA118286C2 (uk) | Білок агоніст рецептора trail | |
| MX2017014822A (es) | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. | |
| MX2018002315A (es) | Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos. | |
| WO2015191666A3 (en) | Raf1 fusions | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| PL3325011T3 (pl) | Białka fuzyjne fragmentów białka ludzkiego do tworzenia uporządkowanych multimeryzowanych kompozycji Fc immunoglobuliny o wzmocnionym wiązaniu dopełniacza | |
| IL254242A0 (en) | Dual signaling fusion proteins and methods of using them to treat diseases | |
| PH12015502421A1 (en) | Artificial transcription factors engineered to overcome endosomal entrapment | |
| MX2024000004A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
| MX388174B (es) | Anticuerpo anti-vegfr2 humano para terapia del cancer anti-angiogenica y dirigida | |
| EA201692482A1 (ru) | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) | |
| IL265942A (en) | A nucleotide sequence expressing an exosome anchor protein for use as a component | |
| HK1257421A1 (zh) | Bag3 组合物和方法 |